Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
European Commission
About
Opens for applications on 2026-10-29. A European Commission call for proposals. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products [1] ) and enhanced health outcomes by ensuring safer and more effective use of medication. Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities. Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines. Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by rob
Who can apply
Usually organisations in EU member states and associated countries, often in a consortium. Some calls are open to partners from other countries. Check the call conditions.
Best for
- Researchers
- NGOs
- Founders
- Location
- Europe
- Cost
- Free to apply
- Organizer
- European Commission
- 43108390
- eu funding